Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Takuji Sato"'
Autor:
Takeo Fujita, Naoya Okada, Takuji Sato, Kazuma Sato, Hisashi Fujiwara, Takashi Kojima, Hiroyuki Daiko
Publikováno v:
BMC Surgery, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background In the present matched-cohort study, we investigated the efficacy of olanexidine gluconate in comparison with chlorhexidine-alcohol as an antiseptic agent in thoracic esophagectomy. Methods A total of 372 patients with esophageal
Externí odkaz:
https://doaj.org/article/4d3ea0d529d742c5a9c8dc73665f6a22
Publikováno v:
Surgical Case Reports, Vol 5, Iss 1, Pp 1-7 (2019)
Abstract Background We encountered an esophageal cancer patient with a double aortic arch (DAA) who underwent radical thoracoscopic esophagectomy with three-field lymph node dissection. A DAA generally makes it difficult to perform upper mediastinal
Externí odkaz:
https://doaj.org/article/426c61d5f6d64c6eb3182ab9830e21de
Autor:
Daisuke Kurita, Takeo Fujita, Yasumasa Horikiri, Takuji Sato, Hisashi Fujiwara, Hiroyuki Daiko
Publikováno v:
Surgical Case Reports, Vol 5, Iss 1, Pp 1-9 (2019)
Abstract Background Non-occlusive mesenteric ischemia (NOMI) is a rare but life-threatening complication of early postoperative enteral feeding. We herein report two patients who developed NOMI during enteral feeding after esophagectomy. Case present
Externí odkaz:
https://doaj.org/article/b5c9e17c1929473faccf1d2502279ae6
Publikováno v:
Surgical Case Reports, Vol 5, Iss 1, Pp 1-4 (2019)
Abstract Background Minimally invasive esophagectomy is considered a beneficial approach to esophageal cancer, although a hiatal hernia occurs more frequently in this approach than in open esophagectomy with reconstruction via the mediastinal route.
Externí odkaz:
https://doaj.org/article/bfbbe406bc034a14b6f155d7c338c9a4
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 8: MLN4924 attenuates tumor growth inhibition by CBS9106 in human xenograft model. (A) SCID mice bearing HCT116 tumor xenografts are treated with vehicle (5% GA, p.o. + 10% HBC, s.c.), CBS9106 (250 mg/kg p.o. once per week), MLN4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e9e48038b36b2f6bd252c9bd54185c9
https://doi.org/10.1158/1535-7163.22499652.v1
https://doi.org/10.1158/1535-7163.22499652.v1
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 2: MLN4924 (50 nM) increases subG1 and DNA content. HCT116 cells are treated with increasing concentrations of MLN4924 (0, 1, 10, or 50 nM) for 72 hours. The population is measured by flow cytometry after staining with propidium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0edb3814a383b57738d98b140c3658f0
https://doi.org/10.1158/1535-7163.22499670
https://doi.org/10.1158/1535-7163.22499670
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 1: CBS9106 reduces CRM1 protein levels through neddylation -mediated degradation in MM.1S cells. (A) MM.1S cells are treated with CBS9106 (50 nM) and/or MLN4924 (100 nM) for indicated period (0-8 hours). (B) Cells are treated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d1dac22335be4ababc4fd71cffe4c02
https://doi.org/10.1158/1535-7163.22499673
https://doi.org/10.1158/1535-7163.22499673
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 6: Inhibitors of autophagy do not interfere with the efficacy of low dose MLN4924. HCT116 cells are treated with CBS9106 (100 nM), MLN4924 (50 nM or 1 microM) or 3-MA (5 mM) alone or in combination for 24 hours. Protein levels of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a8e928ca7b4deccfebb2571b0bc4b5
https://doi.org/10.1158/1535-7163.22499658
https://doi.org/10.1158/1535-7163.22499658
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 7: Schematic representation that summarizes the proposed mechanism of action of CBS9106.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca21ce9db7933b12a8f9bb209b073fb6
https://doi.org/10.1158/1535-7163.22499655
https://doi.org/10.1158/1535-7163.22499655
Autor:
Takumi Kawabe, Daniel D. VonHoff, Donald W. Kufe, Jonathan M. Friedman, Takuji Sato, Keiichi Sakakibara, Naoya Saito
Supplementary Figure 3: The cell growth inhibition and apoptosis by CBS9106 is suppressed by MLN4924 in MM.1S cells. (A) MM.1S cells are treated with the indicated concentration of CBS9106 and/or MLN4924 for 72 hours (n = 6). Cell viability is determ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7511f730693f2044f6d4f116f8115835
https://doi.org/10.1158/1535-7163.22499667
https://doi.org/10.1158/1535-7163.22499667